Harbin, Michelle M.
Kelly, Aaron S.
Dengel, Donald R.
Rudser, Kyle D.
Evanoff, Nicholas G.
Ryder, Justin R.
Article History
Received: 12 August 2019
Revised: 11 September 2019
Accepted: 25 September 2019
First Online: 23 October 2019
Competing interests
: Dr. Kelly serves as a consultant for Novo Nordisk, WW, and Vivus Pharmaceuticals, but does not receive personal or professional income for these activities; he also receives research support (drug/placebo) from Astra Zeneca Pharmaceuticals for an NIDDK-funded clinical trial. Dr. Dengel serves as a paid consultant for Hologic Inc. Dr. Ryder receives research support (drug/placebo) from Boheringer Ingelheim for a clinical trial. The other authors declare no competing interests.